ESC Premium Access

Patients with atrial fibrillation and history of falls are at high risk for bleeding but have less bleeding with apixaban than warfarin: results from the ARISTOTLE trial

Congress Session

About the speaker

Doctor Meena Rao

Duke Clinical Research Institute, Durham (United States of America)
0 follower

8 more presentations in this session

Real world persistence, adherence and switch-over across anticoagulants in atrial fibrillation-a national population-based study.

Speaker: Doctor A. Banerjee (London, GB)

Thumbnail

Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and active cancer: insights from the ARISTOTLE trial

Speaker: Assistant Professor C. Melloni (Durham, US)

Thumbnail

Linking intrinsic factor X activity, a biologically relevant pharmacodynamic marker, to edoxaban plasma concentration and clinical outcomes in the ENGAGE AF-TIMI 48 trial

Speaker: Doctor O. Yin (Edison, New Jersey, US)

Thumbnail

Direct oral anticoagulants in atrial fibrillation patients undergoing cardioversion. Nationwide multicentre study.

Speaker: Miss S. Itainen-Stromberg (Helsinki, FI)

Thumbnail

When should we start thromboprophylaxis? The stroke risk threshold discrepancy between European and U.S. guidelines for atrial fibrillation

Speaker: Mr P. Nielsen (Aalborg, DK)

Thumbnail

Access the full session

New trends in antithrombotic therapy for atrial fibrillation

Speakers: Doctor M. Rao, Doctor A. Banerjee, Assistant Professor C. Melloni, Doctor O. Yin, Miss S. Itainen-Stromberg...
Thumbnail

About the event

Image

ESC CONGRESS 2016

27 August - 31 August 2016

Sessions Presentations

This platform is supported by

logo Novo Nordisk